InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement
MWN-AI** Summary
InterCure Ltd. (Nasdaq: INCR), a prominent cannabis company based in Israel, received a notification from Nasdaq on February 25, 2026, indicating that the company's ordinary shares had failed to meet the minimum bid price requirement of $1.00, as stipulated in Nasdaq Listing Rule 5450(a)(2). This non-compliance was noted after the company’s share prices remained below the threshold for the previous 30 consecutive business days. In response, InterCure has been provided a compliance period of 180 calendar days, extending until August 24, 2026, to rectify this situation.
To regain compliance, InterCure must ensure that its ordinary shares surpass the $1.00 minimum bid price for at least 10 consecutive business days within the designated compliance period. Should the company fail to do so, they may qualify for an additional 180-day compliance period, provided they fulfill certain criteria, including submitting a transfer application to the Nasdaq Capital Market and maintaining compliance with other listing standards.
In its effort to address this deficiency, InterCure plans to monitor its shares' closing price closely, and it is contemplating a reverse share split, subject to necessary approvals. The company remains committed to its business initiatives, which it believes will help restore compliance within the specified timeframe. Throughout this compliance period, InterCure's shares will continue to trade on the Nasdaq Global Market without interruption.
As one of the fastest-growing cannabis firms outside of North America, InterCure operates as a key player in the industry through its wholly-owned subsidiary, Canndoc, which is Israel’s largest licensed cannabis producer. The company emphasizes that its forward-looking statements reflect its current expectations and are subject to various risks and uncertainties.
MWN-AI** Analysis
InterCure Ltd. (INCR) recently received notice from Nasdaq indicating non-compliance with its minimum bid price requirement, as the company's ordinary shares traded below $1.00 for 30 consecutive days. Although receiving such a notification can raise concerns for investors, it’s important to consider the context of this situation and the company's response strategy.
InterCure has been proactive, indicating its intent to monitor share prices and potentially execute a reverse share split to enhance the bid price. This measure, while often seen as a last resort, can effectively consolidate shares, potentially boosting the per-share trading price and helping InterCure regain compliance with Nasdaq's requirements within the allotted timeframe.
Investors should note that InterCure plans to leverage its established position as a leading player in the cannabis market, backed by a strong distribution network and substantial partnerships. As the cannabis sector in Israel and globally continues to expand, the company may still possess significant growth potential despite current bid price challenges. Furthermore, the additional 180-day period for compliance, coupled with the possibility of extending this timeframe, provides InterCure the necessary window to implement corrective measures and improve investor sentiment.
However, the company’s failure to maintain compliance could result in delisting, which would have serious long-term repercussions for shareholders. Therefore, investors should closely monitor developments regarding InterCure’s compliance strategy and effectiveness.
In conclusion, while the current notification presents a challenge for InterCure, the company's strategic initiatives and market position could provide pathways to recovery. Investors may consider this an opportunity to buy into the stock if they believe in the long-term prospects of the cannabis industry and InterCure’s business model. However, patience and vigilance are essential during this compliance period.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NEW YORK and HERZLIYA, Israel, March 03, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) (“InterCure” or the “Company”) today announced that on February 25, 2026 the Company received a written notice (the “Notice”) from the Nasdaq Stock Market LLC indicating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(2), as the Company’s closing bid price for its ordinary shares, or Ordinary Shares, was below $1.00 per share for the last 30 consecutive business days.
Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180-calendar day compliance period, or until August 24, 2026, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Ordinary Shares must meet or exceed $1.00 per share for at least 10 consecutive business days during the 180-calendar day compliance period.
If the Company is not in compliance by August 24, 2026, the Company expects to be eligible for an additional 180-calendar day compliance period. To qualify for this additional time, the Company will be required to submit a transfer application and meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the minimum bid price requirement, and to provide written notice of its intention to cure the deficiency during such period.
The Company currently intends monitor the closing price of its Ordinary Shares and to consider effecting a reverse share split, subject to obtaining all required corporate and regulatory approvals, as part of its plan to regain compliance with the minimum bid price requirement, and believes that this measure, together with its ongoing business and strategic initiatives, will support the restoration of compliance within the applicable timeframe. The Company’s Ordinary Shares will continue to be listed and trade on the Nasdaq Global Market during this period, and are unaffected by the receipt of the written notice from Nasdaq.
If the Company does not regain compliance within the allotted compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company’s Ordinary Shares will be subject to delisting.
This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.
About InterCure (dba Canndoc)
InterCure (dba Canndoc) (Nasdaq: INCR) (TASE: INCR) is the leading, profitable, and one of the fastest growing cannabis companies outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated “seed-to-sale” model to lead the fastest growing cannabis global market outside of North America.
For more information, visit: https://www.intercure.co
Forward-Looking Statements
This press release contains forward-looking statements pursuant to U.S. federal securities laws. Forward-looking statements may include, but are not limited to, statements regarding the Company’s ability to regain compliance with Nasdaq’s minimum bid price requirement, the timing and potential effectiveness of any actions the Company may undertake to cure such deficiency, including the implementation of a reverse share split, and other statements that are not historical facts. These forward-looking statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions, and are based on current expectations, assumptions and assessments of the Company’s management in light of its experience and perception of historical trends, current conditions and expected future developments. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. These risks and uncertainties include, among others, the Company’s ability to meet Nasdaq’s continued listing requirements, obtain required approvals for any corporate actions, including a reverse share split, market conditions, and other factors beyond the Company’s control. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 20-F and in other filings that the Company has made and may make with the U.S. Securities and Exchange Commission. Except as required by law, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact:
InterCure Ltd.
Amos Cohen, Chief Financial Officer
amos@intercure.co
FAQ**
How does InterCure Ltd. (Nasdaq: INCR) plan to regain compliance with Nasdaq Listing Rule 5450(a)(2) amidst the competitive cannabis market in New York and Herzliya, Israel?
What strategic initiatives is InterCure Ltd. (Nasdaq: INCR) implementing to address its stock price challenges, particularly in light of industry trends in both New York and Herzliya?
Given the ongoing compliance issues faced by InterCure Ltd. (Nasdaq: INCR), how might potential regulatory changes in New York and Israel affect its business operations?
How is InterCure Ltd. (Nasdaq: INCR) leveraging its position as a leading cannabis producer in Israel to navigate compliance challenges while facing competition from New York's evolving cannabis market?
**MWN-AI FAQ is based on asking OpenAI questions about Intercure Ltd. (NASDAQ: INCR).
NASDAQ: INCR
INCR Trading
-5.82% G/L:
$0.8171 Last:
26,405 Volume:
$0.85 Open:
